MedTrace Logo

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

NCT04346355 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2020-06-22

No results posted yet for this study

Summary

The clinical study aims at assessing whether early administration of Tocilizumab compared to late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation. The clinical study includes patients with recent-onset COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical ventilation procedures.

Conditions

Interventions

DRUG

Tocilizumab

In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours

Sponsors & Collaborators

  • Azienda USL Reggio Emilia - IRCCS

    lead OTHER_GOV

Principal Investigators

  • Carlo Salvarani, M.D. · Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia

  • Massimo Costantini, Ph.D. · Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-06-06
Completion
2020-06-06

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346355 on ClinicalTrials.gov